You are now leaving GSK’s website

You are now leaving a GSK Website. By clicking this link, you will be taken to a website that is not owned or controlled by GSK, and GSK is not responsible for the content provided on that site.

Continue

Go back

Dovato

Product menu

Powerful Efficacy

Virologically Suppressed Patients

TANGO Logo
TANGO Logo

TANGO Study Design

Confidence with Powerful Efficacy Maintained at Week 96 in Virologically Suppressed Patients

NON-INFERIORITY MAINTAINED WITH NO INCREASED RISK OF VIROLOGICAL FAILURE4
NA
Tango

ITT-E Snapshot analysis. 

Adapted from van Wyk et al, 20202

48-week primary endpoint (HIV-1 RNA ≥50 copies/mL): DOVATO 0.3% (1/369) vs TAF-containing regimens 0.5% (2/372)3

References:

  1. van Wyk J, Ajana F, Bisshop F, et al. Efficacy and safety of switching to dolutegravir/lamivudine fixed-dose 2-drug regimen vs continuing a tenofovir alafenamide-based 3- or 4-drug regimen for maintenance of virologic suppression in adults living with human immunodeficiency virus type 1: Phase 3, randomized, noninferiority TANGO study. Clin Infect Dis. 2020. Doi:10.1093/cid/ciz1243.
  2. van Wyk J, Ajana F, Bisshop F, et al. Switching to DTG/3TC fixed-dose combination (FDC) is non-inferior to continuing a TAF-based regimen (TBR) in maintaining virologic suppression through 96 weeks (TANGO study). Presented at: HIV Glasgow 2020; October 5-8, 2020; Virtual. Slides O441.
  3. van Wyk J, Ajana F, Bisshop F, et al. Efficacy and safety of switching to dolutegravir/lamivudine fixed-dose 2-drug regimen vs continuing a tenofovir alafenamide-based 3- or 4-drug regimen for maintenance of virologic suppression in adults living with human immunodeficiency virus type 1: Phase 3, randomized, noninferiority TANGO study. Clin Infect Dis. 2020. doi:10.1093/cid/ciz1243
  4. Wang R, Horton J, Wright J, et al. Switching from a 3-drug tenofovir alafenamide (TAF)-based regimen to a 2-drug dolutegravir/lamivudine (2DR, DTG/3TC FDC) was not associated with a higher frequency of intermittent viremia in suppressed patients in the TANGO study. Presented at: 17ᵗʰ European AIDS Conference; November 6-9, 2019; Basel, Switzerland. Poster PE 3/15.

Adverse events should be reported directly to the Health Products Regulatory Authority (HPRA) on their website: www.hpra.ie . Adverse events should also be reported to GlaxoSmithKline on 1800 244 255.

Dovato is a registered trade mark of the ViiV Healthcare group of companies or its licensor.

Date of preparation: August 2022 PM-IE-DLL-WCNT-200018